Newly diagnosed histologically confirmed stage I-III, ER, PR and HER2 negative invasive breast cancer as defined by the ASCO CAP guidelines for whom systemic chemotherapy would be indicated based on physician judgment following standard NCCN practice guidelines.
You may not be if
Patients for whom anthracycline, nab-paclitaxel or antibody therapies are contraindicated.
